Company Drug

Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic

By Fineline Cube #Cancer #Clinical trial approval / initiation #Dessight Biomedical #Potential first-in-class #T cell engager
Essight Bio's ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic

Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed with a Phase I clinical trial for patients with advanced solid tumors harboring RAS G12V mutations (KRAS/NRAS/HRAS). ES502 becomes the world’s first TCR×CD3 bispecific T‑cell engager (TCE) targeting the RAS G12V neoantigen to enter clinical development, with potential to address 30–70% of global patients carrying this prevalent oncogenic driver mutation.

Regulatory Milestone

ItemDetail
AgencyU.S. Food and Drug Administration (FDA)
Approval TypeIND clearance for Phase I
ProductES502 Injection
DeveloperShanghai Essight Biotechnology Co., Ltd.
IndicationAdvanced solid tumors with RAS G12V (KRAS/NRAS/HRAS) mutations
SignificanceWorld’s first TCR×CD3 bispecific targeting RAS G12V to enter clinic
Approval Date12 Mar 2026

Product Profile & Mechanism

AttributeES502 Specification
FormatNext‑generation TCR×CD3 bispecific T‑cell engager (TCE)
TargetpHLA complex (RAS G12V neoantigen + HLA)
CD3 EngagementT‑cell recruitment via CD3 binding
Affinity Engineering>100× higher affinity for pHLA vs. CD3 – optimized for tumor‑specific activation with reduced systemic cytokine release
Development StatusIndependently developed by Essight Bio

Mechanistic Differentiation:

  • Precision Targeting: High‑specificity pHLA binding distinguishes mutant RAS from wild‑type
  • Conditional T‑Cell Activation: Affinity differential ensures T‑cell engagement occurs predominantly in tumor microenvironment

Preclinical Evidence

ParameterES502 Performance
Anti‑Tumor ActivitySignificant efficacy across multiple RAS G12V‑positive tumor models
Safety ProfileExcellent tissue/organ tolerance; minimal off‑target toxicity
PharmacokineticsFavorable PK characteristics supporting dosing optimization
Addressable Population30–70% of RAS G12V mutation carriers globally (pan‑tumor indication potential)

Market Context & Strategic Impact

FactorImplication
RAS Mutation PrevalenceRAS G12V present in ~15% of solid tumors (pancreatic, colorectal, lung); represents largest undruggable oncogene class post‑KRAS G12C inhibitor approvals
TCE Market GrowthGlobal bispecific T‑cell engager market projected $8+ billion by 2030; oncology pipeline increasingly targets intracellular neoantigens
Competitive LandscapeFirst‑mover advantage vs. TCR‑T cell therapies (Adaptimmune, Immatics) and other TCR bispecifics in RAS space
Clinical StrategyPan‑tumor basket trial design enables rapid expansion across KRAS/NRAS/HRAS G12V indications
  • Development Pathway: Phase I dose‑escalation in solid tumors; potential for FDA Breakthrough Therapy designation given unmet need in RAS‑mutant cancers
  • Commercial Potential: Peak sales $1–2 billion globally if approved, assuming broad RAS G12V label and competitive efficacy vs. emerging KRAS inhibitors

Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, patient enrollment, and therapeutic potential for ES502. Actual results may differ due to dose‑limiting toxicities, mutation‑specific HLA restriction limitations, and competitive dynamics in the RAS‑targeted oncology space.-Fineline Info & Tech

Related Post

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube
Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Fineline Cube
Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Fineline Cube

You Missed

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Company Drug

Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic